NIKKEI 225
38,456.99 -378.11 (-0.97%) HANG SENG
18,561.34 +81.97 (+0.44%) CRUDE OIL
78.07 -0.31 (-0.40%) GOLD FUTURES
2,315.40 -8.80 (-0.38%) DOW
38,884.26 +31.99 (+0.08%) Bitcoin GBP
50,214.66 -855.74 (-1.68%)
CTMX Nov 2024 2.500 put
| Previous close | 0.7000 |
| Open | 0.6000 |
| Bid | 0.4500 |
| Ask | 0.8000 |
| Strike | 2.50 |
| Expiry date | 2024-11-15 |
| Day's range | 0.6000 - 0.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 81 |
GlobeNewswireCytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA® (pembrolizumab)
- CX-801 is a dually masked, conditionally activated IFNα2b cytokine designed using the CytomX Probody® Therapeutic Platform - - Phase 1 first-in-human study expected to start in first half of 2024 - - Clinical trial will evaluate CX-801 as monotherapy and in combination with KEYTRUDA in patients with advanced metastatic solid tumors including melanoma, renal cell carcinoma and head and neck squamous cell carcinoma - SOUTH SAN FRANCISCO, Calif., May 07, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeuti
ZacksCytomX Therapeutics (CTMX) Surges 214.7%: Is This an Indication of Further Gains?
CytomX Therapeutics (CTMX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
- GlobeNewswire
CytomX Therapeutics to Report First Quarter 2024 Results and Provide an Initial CX-904 Phase 1a Clinical Data Update on May 8, 2024
- CX-904 (masked EGFRxCD3 Probody® T-cell engager) preliminary Phase 1a results to be presented from ongoing dose escalation study - - Management to hold conference call at 5 p.m. EDT / 2 p.m. PDT on May 8th- SOUTH SAN FRANCISCO, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report first quarter 2024 results and provide an initial CX-904 Phase 1a dose
